Effect of acetylsalicylic acid on platelet activation and oxidative profile in a set of Brazilian patients with type 2 diabetes mellitus

Blood Coagulation and Fibrinolysis

Volumn 26, Issue 2, 2015, Pages 123-130

  Duarte, Rita C F ^a   Gonçalves, Líllian H ^b   Campos, Fernanda M F ^a   Filho, Olindo A M ^c   Alves, Michelle T ^a   Fernandes, Ana P ^a   Borges, Karina B G ^a   Dusse, Luci M S ^a   Faria, Mayara C ^a   Gonçalves, Gisele S ^a,d   Bosco, Adriana A ^e   Sandrim, Valéria C ^e   Carvalho, Maria G ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Rede Sarah Hospitals   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d CENTRO UNIVERSITÁRIO NEWTON PAIVA   (Brazil)

^e Hospital Santa Casa de Belo Horizonte   (Brazil)

Author keywords

acetylsalicylic acid; oxidative stress; platelet; thromboxane; type 2 diabetes mellitus

Indexed keywords

2,3 DINORTHROMBOXANE B2; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; D DIMER; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; GLYCOSYLATED HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ANTITHROMBOCYTIC AGENT; THROMBOXANE;

ADULT; ARTICLE; BLOOD SAMPLING; BRAZILIAN; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; BLOOD; BRAZIL; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; MIDDLE AGED;

ASPIRIN; BRAZIL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; THROMBOXANES;

EID: 84922400229     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000199     Document Type: Article

References (44)

1. American Diabetes Association. Diagnosis and classification of diabetes, mellitus. Diabetes Care 2011; 34:S62-S69.
2. Haouari M, Rosado JA. Platelet signalling abnormalities in patients with type 2 diabetes mellitus: a review. Blood Cells Mol Dis 2008; 41:119-123.
3. Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol 2011; 2011:742719.
4. Balasubramaniam K, Viswanathan GN, Marshall SM, Zaman AG. Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res and Pract 2012; 2012:909154.
5. Horstman LL, Jy W, Jimenez JJ, Bidot C, Ahn Ys. New horizons in the analysis of circulating cell-derived microparticles. Keio J Med 2004; 53:210-230.
6. Italiano JE, Mairuhu ATA, Flaumenhaft R. Clinical relevance of microparticles from platelets and megakaryocytes. Curr Opin Hematol 2010; 17:578-584.
7. Morel O, Morel N, Freyssinet JM, Toti F. Platelet microparticles and vascular cells interactions: a checkpoint between the haemostatic and thrombotic responses. Platelets 2008; 19:9-23.
8. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107:1058-1070.
9. Violi F, Pignatelli P. Platelet oxidative stress and thrombosis. Thromb Res 2012; 129:378-381.
10. Medina LO, Veloso CA, de Abreu Borges E, Isoni CA, Calsolari MR, Chaves MM, et al. Determination of the antioxidant status of plasma from type 2 diabetic patients. Diabetes Res Clin Pract 2007; 77:193-197.
11. Vazzana N, Ranalli P, Cuccurullo C, Davi G. Diabetes mellitus and thrombosis. Thromb Res 2012; 129:371-377.
12. Vasconcelos SML, Goulart MOF, Moura JBFM, Manfredini V, Benfato MS, Kubota LT. Espé cies reativas de oxigênio e de nitrogênio, antioxidantes e marcadores de dano oxidativo em sangue humano: principais métodos analíticos para sua determinação. Química Nova 2007; 30:1323-1338.
13. Pulcinelli FM, Biasucci LM, Riondiono S, Guibilato S, Leo A, Di Rinzo L, et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J 2009; 30:1279-1286.
14. American Diabetes Association. Standards of medical care in, diabetes. Diabetes Care 2011; 34:S11-S61.
15. Albert SG, Hasnain BI, Ritter DG, Joist JH, Mooradian AD. Aspirin sensitivity of platelet aggregation in diabetes mellitus. Diabetes Res Clin Pract 2005; 70:195-199.
16. Fitzgerald R, Pirmohamed M. Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther 2011; 130:213-225.
17. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysisofrandomized controlled trials. BMJ 2009; 340:1-8.
18. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300:2134-2141.
19. Haluska MK, Walker LP, Halushka PV. Genetic variation in ciclooxygenase 1: effectsonresponseto aspirin. Clin Pharmacol Ther 2003; 73:122-130.
20. Marín F, González-Conejiro R, Capranzano P, Bass TA, Roldán V, Angiolillo DJ. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol 2009; 54:1041-1057.
21. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989; 83:1778-1781.
22. Cooke GE, Liu-Stratton Y, Ferketich AK, Moeschberger ML, Frid DJ, Magorien RD, et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol 2006; 47:541-546.
23. Papp E, Havasi V, Bene J, Komlosi K, Czopf L, Magyar E, et al. Glycoprotein IIIa gene (PIA2) polymorphism and aspirin resistance: is there any correlation? Ann Pharmacother 2005; 39:1013-1018.
24. Szczeklik A, Musial J, Undas A, Sanak M. Aspirin resistance. J Thromb Haemost 2005; 3:1655-1662.
25. Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS. Genetic polymorphism of the platelet receptors P2Y(12), P2Y(1) and GPIIIa response to aspirin and clopidogrel. Thromb Res; 2007; 119:355-360.
26. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101:1013-1018.
27. Pamukcu B, Oflaz H, Nusanci Y. The role of platelet glycoprotein IIIa polymorphismin the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J 2005; 149:675-680.
28. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29:S1-S48.
29. Hermes-Lima M, Willmore WG, Storey KB. Quantification of lipid peroxidation in tissue extracts based on Fe (III) xylenol orange complex formation. Free Radic Biol Med 1995; 19:271-280.
30. Bode-Boger SM, Boger RH, Schubert M, Frolich JC. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects. Eur J Clin Pharmacol 1998; 54:9-10.
31. Clappers N, van Oijen MG, Sundaresan S, Brouwer MA, Te Morshe RH, Keuper W, et al. The C50Tpolymorphism of the cycloxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetylsalicylic acid. Thromb Haemost 2008; 100:70-75.
32. Pettinella C, Romano M, Stuppia L, Santilli F, Liani R, Davi G. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. Thromb Haemost 2009; 10:687-690.
33. Takahashi S, Ushida M, Komine R, Shimodaira A, Uchida T, Ishihara H, et al. Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms. Thromb Res 2008; 121:509-517.
34. Ertugrul DT, Tutal E, Yildiz M, et al. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95:2897-2901.
35. Cohen HW, Crandall JP, Hailpern SM, Billett HH. Aspirin resistance associated with HbA1c and obesity in diabetic patients. J Diabetes Complications 2008; 22:224-228.
36. Fateh-Moghadam S, Plockinger U, Cabeza N, Htun P, Reuter T, Ersel S, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005; 42:99-103.
37. Pamukcu B, Oflaz H, Onur I, Cimen A, Nisanci Y. Effect of cigarette smoking on platelet aggregation. Clin Appl Thromb Hemost 2011; 17:175-180.
38. Ikonomidis I, Lekakis J, Vamvakou G, Andreotti F, Nihoyannopoulos P. Cigarette smoking is associated with increase circulation proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. Am Heart J 2005; 149:832-839.
39. Hung J, Lam JY, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92:2432-2436.
40. Tan KT, Tayebjee MH, Lim HS, Lip GY. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticles levels. Diabet Med 2005; 22:1657-1662.
41. Lubsczyk B, Kollars M, Hron G, Kyrle PA, Weltermann A, Gartner V. Low dose acetylsalicylic acid and shedding of microparticles in vivo in humans. Eur J Clin Invest 2010; 40:477-482.
42. Bulut D, Becker V, Mugge A. Acetysalicylate reduces endothelial and platelet-derived microparticles in patients with coronary artery disease. Can J Physiol Pharmacol 2011; 89:239-244.
43. Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb Res 2008; 123:8-23.
44. Ristimäe T, Zilmer M, Zilmer K, Kairane C, Kullisaar T, Teesalu R. Effect of low-dose aspirin on the markers of oxidative stress. Cardiovasc Drugs Ther 1999; 13:485-490.